Internis Pharmaceuticals Overview

  • Founded
  • 2010

  • Status
  • Acquired/​Merged

  • Employees
  • 32

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $76.8M

Internis Pharmaceuticals General Information


Provider of vitamin D medicines. The company is engaged in the development and commercialization of medicines for the treatment of bone disorders like osteoporosis and vitamin D3 deficiency.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Other Industries
Parent Company
Primary Office
  • Linthwaite Laboratories
  • West Yorkshire
  • Huddersfield HD7 5QH
  • England, United Kingdom
+44 01484 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Internis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 19-Dec-2014 $76.8M 00.000 000.00 Completed Startup
1. Debt - General 10-Sep-2013 00.000 00.000 Completed Startup
To view Internis Pharmaceuticals’s complete valuation and funding history, request access »

Internis Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Charles Tannenbaum Co-Founder & Co-Chief Executive Officer
Martin Knight Co-Founder & Director
Alan Walker Ph.D Chief Executive Officer
To view Internis Pharmaceuticals’s complete executive team members history, request access »

Internis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial